HaploidenticalHSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts
Open Access
- 13 February 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (3), 263-270
- https://doi.org/10.1182/bloodadvances.2017012005
Abstract
We examined outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) using T-cell receptor alpha beta(+) (TCR alpha beta(+))/CD19(+)-depleted grafts (TCR group, 14 patients) in children with hemoglobinopathies. Patients received a preparative regimen consisting of busulfan, thiotepa, cyclophosphamide, and antithymocyte globulin preceded by fludarabine, hydroxyurea, and azathioprine. The median follow-up among surviving patients was 3.9 years. The 5-year probabilities of overall survival (OS) and disease-free survival (DFS) were 84% and 69%, respectively. The incidence of graft failure was 14%. We compared outcomes to a historical group of 40 patients with hemoglobinopathies who received CD34(+)-selected grafts (CD34 group). The median follow-up of surviving patients for the CD34 group was 7.5 years. The 5-year probabilities of OS and DFS were 78% and 39%, respectively. The CD34 group had a significantly higher incidence of graft failure (45%) than the TCR group (14%) (P = .048). The incidences of grades 2 to 4 acute graft-versus-host disease (GVHD) in the TCR and CD34 groups were 28% and 29%, respectively, and 21% and 10% (P = .1), respectively, for extensive chronic GVHD. Viral reactivation was common in both groups. The overall incidence of posttransplant lymphoproliferative disorders for the entire group was 16%. Among all patients, 5 developed autoimmune hemolytic anemia or thrombocytopenia, with the overall cumulative incidence of 11%. The 2 groups showed suboptimal CD4(+) recovery within the first 6 months of transplantation with no significant difference between groups. These data demonstrate that TCR alpha beta(+)/CD19(+)-depleted grafts are associated with a reduced incidence of graft failure, but delayed immune reconstitution and associated morbidity and mortality remain a significant challenge.Keywords
This publication has 45 references indexed in Scilit:
- Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS deviceCytotherapy, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell TransplantationTransplantation, 2009
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Advances in the allogeneic transplantation for thalassemiaBlood Reviews, 2008
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- High incidence of graft failure in children receiving CD34+ augmented elutriated allografts for nonmalignant diseasesBone Marrow Transplantation, 2003
- Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA HaplotypeNew England Journal of Medicine, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958